Cite
HARVARD Citation
Millns, H. et al. (2014). A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy. Orphanet journal of rare diseases. 9 (1), pp. 1-2. [Online].